87 related articles for article (PubMed ID: 20596672)
41. Time-staggered inhibition of JNK effectively sensitizes chemoresistant ovarian cancer cells to cisplatin and paclitaxel.
Seino M; Okada M; Sakaki H; Takeda H; Watarai H; Suzuki S; Seino S; Kuramoto K; Ohta T; Nagase S; Kurachi H; Kitanaka C
Oncol Rep; 2016 Jan; 35(1):593-601. PubMed ID: 26534836
[TBL] [Abstract][Full Text] [Related]
42. HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells.
Ribeiro JR; Schorl C; Yano N; Romano N; Kim KK; Singh RK; Moore RG
J Ovarian Res; 2016 May; 9(1):28. PubMed ID: 27184254
[TBL] [Abstract][Full Text] [Related]
43. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes.
Kavallaris M; Kuo DY; Burkhart CA; Regl DL; Norris MD; Haber M; Horwitz SB
J Clin Invest; 1997 Sep; 100(5):1282-93. PubMed ID: 9276747
[TBL] [Abstract][Full Text] [Related]
44. Anti-proliferative activity and cell cycle arrest induced by evodiamine on paclitaxel-sensitive and -resistant human ovarian cancer cells.
Zhong ZF; Tan W; Wang SP; Qiang WA; Wang YT
Sci Rep; 2015 Nov; 5():16415. PubMed ID: 26553648
[TBL] [Abstract][Full Text] [Related]
45. Tectorigenin sensitizes paclitaxel-resistant human ovarian cancer cells through downregulation of the Akt and NFκB pathway.
Yang YI; Lee KT; Park HJ; Kim TJ; Choi YS; Shih IeM; Choi JH
Carcinogenesis; 2012 Dec; 33(12):2488-98. PubMed ID: 23027625
[TBL] [Abstract][Full Text] [Related]
46. SMIFH2-mediated mDia formin functional inhibition potentiates chemotherapeutic targeting of human ovarian cancer spheroids.
Ziske MA; Pettee KM; Khaing M; Rubinic K; Eisenmann KM
Biochem Biophys Res Commun; 2016 Mar; 472(1):33-9. PubMed ID: 26898799
[TBL] [Abstract][Full Text] [Related]
47. MicroRNA-136 inhibits cancer stem cell activity and enhances the anti-tumor effect of paclitaxel against chemoresistant ovarian cancer cells by targeting Notch3.
Jeong JY; Kang H; Kim TH; Kim G; Heo JH; Kwon AY; Kim S; Jung SG; An HJ
Cancer Lett; 2017 Feb; 386():168-178. PubMed ID: 27887917
[TBL] [Abstract][Full Text] [Related]
48. BAD partly reverses paclitaxel resistance in human ovarian cancer cells.
Strobel T; Tai YT; Korsmeyer S; Cannistra SA
Oncogene; 1998 Nov; 17(19):2419-27. PubMed ID: 9824152
[TBL] [Abstract][Full Text] [Related]
49. Molecular description of evolving paclitaxel resistance in the SKOV-3 human ovarian carcinoma cell line.
Lamendola DE; Duan Z; Yusuf RZ; Seiden MV
Cancer Res; 2003 May; 63(9):2200-5. PubMed ID: 12727840
[TBL] [Abstract][Full Text] [Related]
50. Establishment of a New Ovarian Cancer Cell Line CA5171.
Chiang YC; Cheng WF; Chang MC; Lu TP; Kuo KT; Lin HP; Hsieh CY; Chen CA
Reprod Sci; 2015 Jun; 22(6):725-34. PubMed ID: 25394645
[TBL] [Abstract][Full Text] [Related]
51. Epithelial-to-Mesenchymal Transition in Paclitaxel-Resistant Ovarian Cancer Cells Is Downregulated by Luteolin.
Dia VP; Pangloli P
J Cell Physiol; 2017 Feb; 232(2):391-401. PubMed ID: 27198989
[TBL] [Abstract][Full Text] [Related]
52. Aurora B expression in metastatic effusions from advanced-stage ovarian serous carcinoma is predictive of intrinsic chemotherapy resistance.
Hetland TE; Nymoen DA; Holth A; Brusegard K; Flørenes VA; Kærn J; Tropé CG; Davidson B
Hum Pathol; 2013 May; 44(5):777-85. PubMed ID: 23114921
[TBL] [Abstract][Full Text] [Related]
53. [Chemotherapy resistance induced by interleukin-6 in ovarian cancer cells and its signal transduction pathways].
Wang Y; Li LZ; Ye L; Niu XL; Liu X; Zhu YQ; Sun WJ; Liang YJ
Zhonghua Fu Chan Ke Za Zhi; 2010 Sep; 45(9):691-8. PubMed ID: 21092551
[TBL] [Abstract][Full Text] [Related]
54. WWOX sensitises ovarian cancer cells to paclitaxel via modulation of the ER stress response.
Janczar S; Nautiyal J; Xiao Y; Curry E; Sun M; Zanini E; Paige AJ; Gabra H
Cell Death Dis; 2017 Jul; 8(7):e2955. PubMed ID: 28749468
[TBL] [Abstract][Full Text] [Related]
55. Low expression of S100P associated with paclitaxel resistance in ovarian cancer cell line.
Gao JH; He ZJ; Wang Q; Li X; Li YX; Liu M; Zheng JH; Tang H
Chin Med J (Engl); 2008 Aug; 121(16):1563-8. PubMed ID: 18982869
[TBL] [Abstract][Full Text] [Related]
56. Proteomic identification of paclitaxel-resistance associated hnRNP A2 and GDI 2 proteins in human ovarian cancer cells.
Lee DH; Chung K; Song JA; Kim TH; Kang H; Huh JH; Jung SG; Ko JJ; An HJ
J Proteome Res; 2010 Nov; 9(11):5668-76. PubMed ID: 20858016
[TBL] [Abstract][Full Text] [Related]
57. A chemoresponse assay for prediction of platinum resistance in primary ovarian cancer.
Krivak TC; Lele S; Richard S; Secord AA; Leath CA; Brower SL; Tian C; Moore RG
Am J Obstet Gynecol; 2014 Jul; 211(1):68.e1-8. PubMed ID: 24530815
[TBL] [Abstract][Full Text] [Related]
58. Galectin-3 induces ovarian cancer cell survival and chemoresistance via TLR4 signaling activation.
Cai G; Ma X; Chen B; Huang Y; Liu S; Yang H; Zou W
Tumour Biol; 2016 Sep; 37(9):11883-11891. PubMed ID: 27059733
[TBL] [Abstract][Full Text] [Related]
59. Actin divides to conquer.
Maiato H; Ferrás C
Science; 2017 Aug; 357(6353):756-757. PubMed ID: 28839062
[No Abstract] [Full Text] [Related]
60. In oxygen-deprived tumor cells ERp57 provides radioprotection and ensures proliferation via c-Myc, PLK1 and the AKT pathway.
Ocklenburg T; Neumann F; Wolf A; Vogel J; Göpelt K; Baumann M; Baumann J; Kranz P; Metzen E; Brockmeier U
Sci Rep; 2021 Mar; 11(1):7199. PubMed ID: 33785835
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]